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Case description
In this case report, we present a rare case of central nervous
system demyelination secondary to infliximab therapy.
A 47-year-old gentleman with a 15-year history of left
sided ulcerative colitis presented to the gastroenterology
clinic with a 1-month history of bloody diarrhoea asso-
ciated with a significantly elevated faecal calprotectin.
A trial of oral and rectal mesalazine as well as oral ster-
oids proved ineffective. He had previously been intolerant
to both Azathioprine and 6-mercaptopurine. Decision was
made to escalate his treatment to methotrexate and inflix-
imab 5 mg/kg (originator). He was managed in the out-
patient setting and did not require hospitalization.
First infliximab infusion was given on 14 May 2020.
Second and third infusion were given two and six weeks
after respectively. One week prior to the third infusion, he
began to develop tingling and numbness down the right
side of his body and he felt his right foot was more sensitive
to changes in temperature. His Methotrexate was stopped
but it was decided to proceed with giving the third infusion
of infliximab. In the following two weeks he then developed
weakness in the left leg and reported urinary hesitancy.
He was reviewed in the ambulatory unit by the neur-
ologist twelve days following the start of his neurological
symptoms. On clinical examination, cranial nerves were
intact. He had good muscle bulk and no focal wasting.
Tone was normal bilaterally, but power was mildly
reduced on the left, 4/5 in wrist, digits, hip flexion and
knee extension. Reflexes were present bilaterally, but
the supinator, knee and ankle reflexes were brisk on the
left. Coordination was intact. There was reduced proprio-
ception and temperature sensation on the right side, with a
sensory level just below the clavicle, whilst touch, vibra-
tion and two-point discrimination were preserved bilat-
erally. Plantars were downgoing bilaterally.
An urgent MRI of the spine was subsequently arranged
which revealed a right sided intramedullary cord lesion at
C4 with some focal eccentric enhancement (Figure 1).
A subsequent MRI of his head revealed white matter
plaques in the cerebral hemisphere and corpus callosum
(Figure 2). The post contrast sequences (not shown)
showed no features of active demyelination.
CSF analysis was positive for IgG oligoclonal bands.
Serum oligoclonal band testing revealed no abnormal-
ities. These findings supported a diagnosis of
Brown-Sequard syndrome secondary to a cord lesion
due to multiple sclerosis (MS). The diagnosis of MS
was based on evidence of widespread inflammation in
the brain and the spinal cord in addition to positive oligo-
clonal bands in the CSF, which can be used as criteria for
dissemination in time (2017 revised McDonald criteria).1
His infliximab was discontinued after his third infusion
with no deterioration to his colitis and his neurology grad-
ually started to improve two weeks later. He had a further
flare of his MS a few months later manifesting as diplopia.
Repeat MRI showed signal change involving the right deep
parietal lobe that was more conspicuous than before prob-
ably representing some disease progression. Following dis-
cussion in the neuroinflammatory MDT it was decided that
given the significant inflammatory activity he should be
started on Natalizumab. Although this is not a licensed
treatment for ulcerative colitis, being an anti-integrin, it
was thought that it may also have the added benefit of redu-
cing the risk of colitis flare. His first Natalizumab infusion
was eight months after his last infliximab infusion.
Discussion
Anti-TNF drugs are an established therapeutic option in
treatment of a number of inflammatory conditions includ-
ing inflammatory bowel disease. Although these drugs
can prove very effective, they can be associated with
potentially serious adverse effects. One rare but poten-
tially serious side effect is demyelinating disease.
A large French study, carried out between 2005 and
2008, identified 33 patients who developed demyelinating
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disorder during anti-TNF therapy with either infliximab
(n= 15), etanercept (n= 12) or adalimumab (n= 6)
with two patients having a positive rechallenge.2
Several other studies have also shown an association
between optic neuritis and demyelinating disease with
the use of etanercept, infliximab and adalimumab.3,4 In
randomised controlled trials and postmarketing studies,
the prevalence of demyelination with infliximab,
Figure 1. Sagittal T2 and coronal T1 post contrast sequences show an expansile lesion at the level of C4 with a focal area of
enhancement in the left lateral cord, in keeping with active demyelination.
Figure 2. T2 FLAIR sequence showing periventricular and callosal lesions which are disseminated in space.
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etanercept or adalimumab has been reported to range
between 0.05 and 0.2%.5
Causal relationship between anti-TNF therapy and
demyelinating disease remains unclear and questions
have been raised as to whether demyelinating events
in patients receiving anti-TNF therapy are the result
of uncovering latent MS, onset of novel demyelinat-
ing event or merely an accidental coexistence of the
two disorders.6 Nevertheless, NICE guidelines
suggest anti-TNF therapy should not be given when
there is a clear history of demyelinating disease,
may be best avoided if there is a possible history of
demyelinating disease or a strong family history of
demyelination and should be withdrawn if demyelin-
ation occurs.7
With regards to the more novel biologic agents used in
IBD, there is currently no data to suggest an association
between Vedolizumab or Ustekinumab and demyelinat-
ing disorders suggesting these may be preferential in
patients with personal or family history of demyelinating
disease.
Brown-Sequard syndrome is a rare entity resulting
from hemisection injury of the spinal cord, often in
the cervical cord region.8,9 It is characterized by ipsilat-
eral loss of motor function, vibration and propriocep-
tion below the level of the lesion secondary to
damage to corticospinal tracts and contralateral loss of
pain and temperature secondary to damage to the spi-
nothalamic tracts. It is typically caused by traumatic
spinal cord injury; however, there are also several non-
traumatic causes. These include tumours, infections,
disc herniation, autoimmune diseases and multiple
sclerosis.9
MRI is the imaging of choice with CT scan performed
in those unable to have an MRI. Imaging typically reveals
a high T2 signal weighted lesion usually localised to one
side of the spinal cord.10
A detailed history may identify patients at risk of
demyelination with initiation of anti TNF therapy.
However, if there is uncertainty it may be appropriate to
arrange an MRI of brain and, if previous possible symp-
toms suggest, spinal cord before commencing the bio-
logic treatment to detect lesions which could suggest
pre-existing demyelination.
Written informed consent was obtained from the patient
for the publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal on request.
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